Medicare to cover GLP-1 drugs for weight loss for the first time starting July 1. Here's what to know.
CBS News
Last updated: June 30, 2026
Medicare is set to cover GLP-1 drugs for weight loss for eligible beneficiaries, marking a significant policy shift. This coverage begins on July 1st and will involve a monthly copay.
Medicare will, for the first time, provide coverage for GLP-1 drugs when prescribed specifically for weight loss. This change applies to eligible Medicare beneficiaries. The estimated monthly copay for these medications will be $50. This development signifies a notable expansion of Medicare's benefits, addressing a long-standing demand for coverage of obesity treatments. Previously, Medicare primarily covered these drugs for diabetes management, not as a standalone weight-loss therapy. The decision is based on emerging clinical evidence supporting the efficacy of GLP-1 agonists in promoting significant and sustained weight loss. The coverage aims to make these increasingly popular and effective treatments more accessible to a wider population facing challenges with obesity. It acknowledges obesity as a serious health condition warranting medical intervention and coverage. The $50 copay is intended to reduce the financial burden on beneficiaries, though out-of-pocket costs could still vary based on individual plan details and other healthcare needs. This policy update reflects a growing recognition of the medical necessity and public health implications of addressing obesity.
